Bruker Corporation(BRKR) Stock Research - Grey Stern Research

Bruker Corporation (BRKR) Stock Analysis

$68.26 (2.19%)

BRKR Financial Performance


Use the table below to view Bruker Corporation's financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q2 - 2024

Metric Value Ranking among Peers
Price $66.80 -
52 Week Low $53.79 -
52 Week High $94.86 -
Market Cap $10.1 Billion 2/17
Gross Margin 49% 15/17
Profit Margin 1% 6/17
EBITDA margin 15% 7/17
Q2 - 2024 Revenue $800.7 Million 2/17
Q2 - 2024 Earnings $7.6 Million 5/17
Q2 - 2024 Free Cash Flow -$23.5 Million 16/17
Trailing 4 Quarters Revenue $3.1 Billion 3/17
Trailing 4 Quarters Earnings $352.1 Million 2/17
Quarterly Earnings Growth -87% 15/17
Annual Earnings Growth 23% 7/17
Quarterly Revenue Growth 17% 7/17
Annual Revenue Growth 14% 6/17
Cash On Hand $169.7 Million 5/17
Short Term Debt $26.4 Million 5/17
Long Term Debt $2.1 Billion 2/17

Bruker Corporation Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Bruker Corporation's metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 28.72 4/17
PS 3.24 9/17
PB 5.54 4/17
PC 59.59 4/17
Liabilities to Equity 2.28 2/17
ROA 0.06 1/17
ROE 0.20 1/17
Current Ratio 1.45 16/17
Quick Ratio 0.04 15/17
Long Term Debt to Equity 1.19 2/17
Debt to Equity 1.27 2/17
Burn Rate 2.01 12/17
Cash to Cap 0.02 13/17
CCR -3.09 16/17
EV to EBITDA 102.37 2/17
EV to Revenue 3.91 9/17

Company Details

Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.

CEO: Dr. Frank Laukien

Website: https://www.bruker.com

Address: 40 MANNING RD Billerica, MASSACHUSETTS

Exchange: NASDAQ Global Select

Industry: Medical Devices

Bruker Corporation Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Bruker Corporation. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Glaukos Corporation GKOS $7.1 Billion
Zimmer Biomet Holdings, Inc. ZBH $21.7 Billion
LivaNova PLC LIVN $2.8 Billion
AxoGen, Inc. AXGN $643.0 Million
NuVasive, Inc. NUVA $2.1 Billion
iRhythm Technologies, Inc. IRTC $2.3 Billion
Bio-Rad Laboratories, Inc. BIO $9.6 Billion
Integer Holdings Corporation ITGR $4.4 Billion
CONMED Corporation CNMD $2.3 Billion
Heska Corporation HSKA $1.3 Billion
Surmodics, Inc. SRDX $562.1 Million
Orthofix Medical Inc. OFIX $622.2 Million
OrthoPediatrics Corp. KIDS $707.3 Million
Pulmonx Corporation LUNG $335.9 Million
Paragon 28, Inc. FNA $574.8 Million
Artivion, Inc. AORT $1.1 Billion
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
BRKR Income Statements
Quarter Year Revenue Earnings
Q2 2024 $ 800.7 Million $7.6 Million
Q1 2024 $ 721.7 Million $50.9 Million
Q4 2023 $ 854.5 Million $205.5 Million
Q3 2023 $ 742.8 Million $88.1 Million
Q2 2023 $ 681.9 Million $57.1 Million
Q1 2023 $ 685.3 Million $76.5 Million
Q4 2022 $ 708.4 Million $97.4 Million
Q3 2022 $ 638.9 Million $88.1 Million

View All

BRKR Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q2 2024 $169.7 Million $5.9 Billion $2.3 Billion $1.8 Billion
Q1 2024 $340.1 Million $4.5 Billion $1.5 Billion $1.5 Billion
Q4 2023 $488.3 Million $4.2 Billion $1.3 Billion $1.4 Billion
Q3 2023 $363.6 Million $3.8 Billion $1.2 Billion $1.2 Billion
Q2 2023 $574.8 Million $3.9 Billion $1.2 Billion $1.3 Billion
Q1 2023 $597.9 Million $3.8 Billion $1.2 Billion $1.2 Billion
Q4 2022 $645.5 Million $3.6 Billion $1.2 Billion $1.1 Billion
Q3 2022 $626.2 Million $3.3 Billion $1.2 Billion $948.0 Million

View All

BRKR Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q2 2024 -$23.5 Million -$24.6 Million -$170.4 Million
Q1 2024 $400,000 -$21.4 Million -$148.2 Million
Q4 2023 $174.0 Million -$31.5 Million $124.7 Million
Q3 2023 $17.2 Million -$26.9 Million -$211.3 Million
Q2 2023 -$10.5 Million -$23.5 Million -$23.2 Million
Q1 2023 $62.5 Million -$25.0 Million -$47.3 Million
Q4 2022 $134.7 Million -$24.4 Million $19.4 Million
Q3 2022 $11.8 Million -$57.7 Million -$97.0 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions